menu
    • menu
    [{"orgOrder":0,"company":"Luxa Biotechnology","sponsor":"National Institutes of Health | National Eye Institute | Regenerative Research Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"RPESC-RPE-4W","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Luxa Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Luxa Biotechnology \/ National Institutes of Health | National Eye Institute | Regenerative Research Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Luxa Biotechnology \/ National Institutes of Health | National Eye Institute | Regenerative Research Foundation"},{"orgOrder":0,"company":"Luxa Biotechnology","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Funding","leadProduct":"RPESC-RPE-4W","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Luxa Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Luxa Biotechnology \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Luxa Biotechnology \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"Luxa Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"RPESC-RPE-4W","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Luxa Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Luxa Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Luxa Biotechnology \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Luxa Biotechnology

    Menu

    Luxa Biotechnology

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Luxa Biotechnology

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Luxa Biotechnology

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RPESC-RPE-4W

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Luxa Biotechnology Receives FDA RMAT for Dry Macular Degeneration Therapy

                            Details : RPESC-RPE-4W is an retinal pigment epithelial stem cell (RPESC) therapy, which effectively replaces the native RPE cells lost during AMD disease progression.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            February 18, 2025

                            Lead Product(s) : RPESC-RPE-4W

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Luxa Biotechnology

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Luxa Biotechnology

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RPESC-RPE-4W

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I/ Phase II

                            Sponsor : California Institute for Regenerative Medicine

                            Deal Size : $4.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Luxa Awarded $4M Grant to Support Clinical Trial for Macular Degeneration Therapy

                            Details : The grant from CIRM supports the ongoing early-stage clinical trials involving RPESC-RPE-4W transplantation for treating dry age-related macular degeneration.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            May 01, 2024

                            Lead Product(s) : RPESC-RPE-4W

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : California Institute for Regenerative Medicine

                            Deal Size : $4.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Luxa Biotechnology

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Luxa Biotechnology

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RPESC-RPE-4W

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I/ Phase II

                            Sponsor : National Institutes of Health | National Eye Institute | Regenerative Research Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-relat...

                            Details : RPESC-RPE-4W is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Macular Degeneration.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            November 13, 2020

                            Lead Product(s) : RPESC-RPE-4W

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : National Institutes of Health | National Eye Institute | Regenerative Research Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth